MSD Korea launches Brenzys™ in Korea for the first time

Published: 2015-12-07 14:49:42

Updated: 2015-12-07 14:49:42

On the 3^rd, MSD Korea(CEO Dong-wook Hyun) announced Samsung Bioepis will launch Brenzys™, a biosimilar the company developed and commercializes, for the first time in the world.

Like etanercept, the original, Brenzys™ can be used as a treatment for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis (ankylosing spondylitis and non-radiographic anxial spondyloarthritis) and psoriasis. ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.